Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273621 | 0.84 | KDM4E (0.41) | NR1H2ALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL3267227 | 0.78 | BRD4 (0.45) | AURKACDK2CCNA2NR1H2TLR9 | |
| SCHEMBL3555267 | 0.77 | ALDH1A1 (0.34) | ALDH1A1KMT2APDK2 | |
| SCHEMBL4663206 | 0.73 | ALPL (0.34) | ALDH1A1 | |
| SCHEMBL25301126 | 0.73 | ACLY (0.33) | ALDH1A1 | |
| SCHEMBL30482620 | 0.73 | ACLY (0.33) | ALDH1A1 | |
| SCHEMBL25664103 | 0.72 | ACSS2 (0.32) | — | |
| SCHEMBL7489186 | 0.71 | NR1H2 (0.36) | NR1H2TLR9ALDH1A1KMT2AGABRG2 | |
| SCHEMBL25250692 | 0.71 | ACLY (0.31) | — | |
| SCHEMBL30482627 | 0.71 | ACLY (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963311-B1 | CHROMANE SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS ACID PUMP INHIBITORS | RAQUALIA PHARMA INC (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-7723321-B2 | Chromane substituted benzimidazole derivatives | RAQUALIA PHARMA INC. (JP) | 2010-05-25 | — | — | US | disclosed |
| EP-1963311-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS ACID PUMP INHIBITORS | Pfizer, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072146-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS ACID PUMP INHIBITORS | PFIZER JAPAN INC. (JP) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142448-A1 | Chromane Substituted Benzimidazole Derivatives | PFIZER INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142448-A1 | Chromane Substituted Benzimidazole Derivatives | HRH2, HRH4, HRH1 | AURKA 3922/4885CDK2 3050/4885CCNA2 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.